Haematologica最新文献

{"title":"HBV infection in the era of T-cell engagers in multiple myeloma: unresolved challenges and unmet needs. Comment on: Hepatitis B virus reactivation following T-cell engager therapy in multiple myeloma despite negative hepatitis B core antibody serology: implications for screening in patients with hematological malignancies.","authors":"Angela Rago,Lorenzo Ridola,Tommaso Caravita Di Toritto","doi":"10.3324/haematol.2025.288942","DOIUrl":"https://doi.org/10.3324/haematol.2025.288942","url":null,"abstract":"Not available.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"501 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beating the STATs: targeting the metabolome in acute myeloid leukemia.","authors":"Boaz Nachmias,Ofir Wolach","doi":"10.3324/haematol.2025.288349","DOIUrl":"https://doi.org/10.3324/haematol.2025.288349","url":null,"abstract":"Not available.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"161 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dental plaque microbiota following allogeneic hematopoietic cell transplantation and risk of chronic graft-versus-host disease.","authors":"Hakan Gem,Maryam Ebadi,Gale Sebastian,Rania Abasaeed,Michele Lloid,Samuel S Minot,David R Dean,Armin Rashidi","doi":"10.3324/haematol.2025.288279","DOIUrl":"https://doi.org/10.3324/haematol.2025.288279","url":null,"abstract":"Microbiota disruptions have been associated with short-term complications after allogeneic hematopoietic cell transplantation (alloHCT). However, only a few studies have examined the relationship between dysbiosis and chronic graft-versus-host disease (cGVHD), the main long-term immunologic toxicity of alloHCT. Considering the role of oral microbiota in systemic inflammatory diseases, we evaluated whether oral microbiota at day 28 post-HCT corresponding to clinical recovery from the acute events after transplantation is associated with subsequent cGVHD. Shotgun metagenomic sequencing of 207 saliva and supragingival plaque samples collected longitudinally at baseline (pre-conditioning), day +28, and day +84 from 37 patients (11 with subsequent moderate/severe cGVHD) revealed a significant association between day +28 plaque microbiota composition and cGVHD. Two orthogonal statistical approaches demonstrated Streptococcus sanguinis and Prevotella loescheii in day +28 plaque to be associated with cGVHD. Metagenome-based functional analysis identified 4 microbial metabolic pathways associated with future cGVHD, two of which were highly attributed to S. sanguinis. These pathways - ethanolamine utilization and glycerol metabolism - increase bacterial fitness by providing an alternative carbon/nitrogen source and improving survival in inflamed tissues. Our findings propose a novel mechanism by which the early post-transplant dental biofilm may contribute to cGVHD months later, offering a potential target for early prophylactic intervention.","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"24 1","pages":""},"PeriodicalIF":10.1,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired Bernard-Soulier syndrome as the presenting feature of GATA2-related myeloid neoplasm in an adolescent: an insight into the mechanisms underlying the platelet defect.","authors":"Laureano J Kamiya, María D Morell, Rosana F Marta, Marina Narbaitz, Christophe Marzac, Nora P Goette, Geraldine De Luca, Paola R Lev, María F Metrebian, Daiana Ganiewich, Andrea S Llera, Hana Raslova, Paula G Heller, Ana C Glembotsky","doi":"10.3324/haematol.2025.287580","DOIUrl":"10.3324/haematol.2025.287580","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"2240-2245"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399949/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144225317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MAP-kinase mutations and aortic lesions are associated with distribution of circulating monocytes in histiocytosis.","authors":"Jerome Razanamahery, Helene Greigert, Matthias Papo, Jean-Francois Emile, Julien Guy, Francesco Pegoraro, Julien Haroche, Sylvain Audia, Maxime Samson, Bernard Bonnotte","doi":"10.3324/haematol.2024.286716","DOIUrl":"10.3324/haematol.2024.286716","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"2181-2186"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic and clinical characteristics of patients with Shwachman Diamond syndrome with special consideration of treatment with granulocyte-colony stimulating factor.","authors":"Sabine Mellor-Heineke, Julia Skokowa, Natali Gerschmann, Ekaterina Deordieva, Ivan Tesakov, Sally Kinsey, Maja Klaudel-Dreszler, Piero Farruggia, Martina Sukova, Mikael Sundin, Yasmine El Chazli, Tania N Masmas, Leen Willems, Georg Ebetsberger-Dachs, Hans C Erichsen, Orna Steinberg-Shemer, Anna Shcherbina, Karl Welte, Cornelia Zeidler","doi":"10.3324/haematol.2024.286119","DOIUrl":"10.3324/haematol.2024.286119","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"2171-2175"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399964/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143718800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A CHIP off the old (MDS) block.","authors":"Selina M Luger, Bryan T Ciccarelli","doi":"10.3324/haematol.2025.287929","DOIUrl":"10.3324/haematol.2025.287929","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":"110 9","pages":"1898-1899"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144951895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow-up.","authors":"Andrew J Portuguese, Jennifer J Huang, Yein Jeon, Mahnoosh Taheri, Aya Albittar, Emily C Liang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, Ryan S Basom, Qian Vicky Wu, David G Maloney, Jordan Gauthier","doi":"10.3324/haematol.2024.287010","DOIUrl":"10.3324/haematol.2024.287010","url":null,"abstract":"<p><p>Lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel) are Food and Drug Administration- and European Medicines Agency-approved chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory large B-cell lymphoma (LBCL). However, comparative real-world analyses of their efficacy and toxicity with extended follow-up are lacking. We conducted a retrospective study of 160 LBCL patients treated at the Fred Hutchinson Cancer Center with commercial liso- cel or axi-cel per standard of care. Using inverse probability of treatment weighting (IPTW) to mitigate treatment allocation bias and multivariable adjustments to minimize other sources of confounding, we assessed the impact of CAR T-cell product type on outcomes. Axi-cel was associated with significantly higher rates of cytokine release syndrome (CRS; grade [G]1+: adjusted odds ratio [aOR] =4.27; P=0.004; G2+: aOR=2.88; P=0.006), immune effector cell-associated neurotoxicity syndrome (ICANS; G1+: aOR=2.10; P=0.048), and immune effector cell-associated hematotoxicity (ICAHT; G1+: aOR=8.09; P<0.001; G2+: aOR=3.86; P=0.001). Axi-cel was also associated with more frequent use of supportive care measures, such as tocilizumab (aOR=2.50; P=0.017), dexamethasone (aOR=2.77; P=0.007), and cefepime (aOR=3.37; P=0.001). We could not confirm statistically significant differences in the response rates and survival outcomes after liso-cel versus axi-cel (complete response: aOR=1.12; P=0.8; overall survival: adjusted hazard ratio [aHR] =1.34; P=0.3; progression-free survival: aHR=0.97; P=0.9; duration of response: aHR=0.89; P=0.7; cumulative incidence of relapse: aHR=0.92; P=0.8). In summary, although axicel was associated with greater toxicity requiring more intensive management, the response rates and survival outcomes were comparable between axi-cel and liso-cel.</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"2040-2054"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143614728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial.","authors":"Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T Shafer, Meral Beksac, Thierry Facon","doi":"10.3324/haematol.2024.287200","DOIUrl":"10.3324/haematol.2024.287200","url":null,"abstract":"<p><p>Patients with multiple myeloma (MM) meeting frailty criteria have worse outcomes than those identified as non-frail. Here, we present a post hoc subgroup analysis of IMROZ, a global, phase III, open-label study investigating isatuximab (Isa) with bortezomib, lenalidomide, and dexamethasone (VRd) followed by Isa-Rd (N=265) versus VRd followed by Rd (N=181) in newly diagnosed transplant-ineligible MM (Ti NDMM) patients using the simplified International Myeloma Working Group (sIMWG) frailty score. Although patients aged >80 years were excluded, there was no exclusion for patients meeting frailty criteria. All patients received standard VRd/Rd dosing; Isa-VRd patients received intravenous Isa (cycle 1, 10 mg/kg once weekly; cycles 2-17, once every 2 weeks; subsequent cycles, once every 4 weeks). Patients with a frailty score of 0/1 were considered nonfrail; scores ≥2 were frail. Using this scoring, 26.7% of patients were frail (26.0% Isa-VRd; 27.6% VRd), and 72.0% non-frail (72.8% Isa-VRd; 70.7% VRd). After a median follow-up of 59.7 months, Isa-VRd significantly improved progression-free survival versus VRd in frail patients (hazard ratio [HR] =0.518; 95% confidence interval [CI]: 0.294-0.912; P=0.0227) and non-frail patients (HR=0.615; 95% CI: 0.419-0.903; P=0.0131). Significantly more frail patients receiving Isa-VRd than VRd achieved minimal residual disease negativity and complete response (odds ratio=3.459; 95% CI: 1.495-8.006; P=0.0030 at 10-5 by next-generation sequencing). Rates of treatment-emergent adverse events leading to definitive discontinuation were similar between both arms regardless of frailty status. This post hoc subgroup analysis of the IMROZ trial demonstrated that Isa-VRd is an effective option with a manageable safety profile for frail patients with Ti NDMM (clinicaltrials gov. Identifier: NCT03319667).</p>","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"2139-2150"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of response to pacritinib therapy and survival among 60 Mayo Clinic patients with myelofibrosis treated outside of clinical trials.","authors":"Maymona Abdelmagid, Jeanne M Palmer, Aref Al-Kali, Mehrdad Hefazi, James Foran, Kebede H Begna, Cecilia Y Arana Yi, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi","doi":"10.3324/haematol.2025.287576","DOIUrl":"10.3324/haematol.2025.287576","url":null,"abstract":"","PeriodicalId":12964,"journal":{"name":"Haematologica","volume":" ","pages":"2224-2229"},"PeriodicalIF":7.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12399963/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}